Home › Burkitt Lymphoma › Ohio › Cincinnati
Burkitt Lymphoma clinical trials in Cincinnati, OH
12 studies for Burkitt Lymphoma are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi away
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
RecruitingPhase 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mi away
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RecruitingPhase 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RecruitingPhase 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- University of Cincinnati, Cincinnati
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL14 studies
- Atlanta, GA12 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Boston, MA10 studies
- Kansas City, MO10 studies
- Aurora, CO10 studies
- Los Angeles, CA10 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer35 studies
- Cancer (all types)27 studies
- Breast Cancer25 studies
- Heart Failure24 studies
- Colorectal Cancer21 studies
- Acute Myeloid Leukemia20 studies
- Metastatic Cancer20 studies
- Ovarian Cancer19 studies
- Lung Cancer19 studies
- Obesity19 studies
- Prostate Cancer18 studies
- Multiple Myeloma17 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.